Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
NCT06630221 · Abhay Singh, MD MPH · PHASE2 · suspended · last registry update 2026-10-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding unavailable” | – | Registry record, Abhay Singh, MD MPH |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MPL within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-23Results posted on the registry: The First Affiliated Hospital of Soochow University, Decitabine + Granulocyte Colony-Stimulating Factor (NCT05907499)
- 2026-10-16Also stopped (withdrawn): Anjali Sharathkumar, Romiplostim + Immunosuppressive therapy (IST) (NCT07001254)
- 2026-10-09Also stopped (terminated): University of California, Davis, Eltrombopag (NCT04485416)
- 2026-09-16Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Eltrombopag (NCT03206086)
- 2026-08-26Phase 3 first posted: Swedish Orphan Biovitrum, Avatrombopag 20 mg Oral Tablet (NCT07786922)
- 2026-08-10Results posted on the registry: Novartis Pharmaceuticals, Eltrombopag + hATG (NCT03025698)
- 2026-07-13Phase 3 first posted: Amgen, Romiplostim + Predniso(lo)ne (NCT07700238)
- 2026-06-04Also stopped (withdrawn): Peking Union Medical College Hospital, Romiplostim N01 (NCT07532408)
- 2026-06-04Also stopped (withdrawn): Peking Union Medical College Hospital, Cyclosporine (CsA) + Thrombopoietin Receptor Agonist (NCT07523009)
- 2026-02-11Results posted on the registry: Amgen, Romiplostim (NCT03362177)
- 2026-01-15Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., Romiplostim N01 + Cyclosporine A (CsA) (NCT07345000)
- 2026-01-09Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Eltrombopag + Cyclosporine (NCT04304820)
- 2025-12-16Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., Hetrombopag Olamine + Hetrombopag Olamine; Hetrombopag Olamine Placebo (NCT07286032)
- 2025-12-12Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Avatrombopag+All trans retinoic acid + Avatrombopag (NCT07278908)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision